Cargando…

Virus-like particles (VLP) in prophylaxis and immunotherapy of allergic diseases

BACKGROUND: Apart from active allergen avoidance, immunotherapy is regarded as the most effective form of treatment available for type I allergies. Such treatments involve the administration of allergen preparations in various forms and by various routes. Virus-like particles (VLPs) offer a very eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Klimek, Ludger, Kündig, Thomas, Kramer, Matthias F., Guethoff, Sonja, Jensen-Jarolim, Erika, Schmidt-Weber, Carsten B., Palomares, Oskar, Mohsen, Mona O., Jakob, Thilo, Bachmann, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Medizin 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267129/
https://www.ncbi.nlm.nih.gov/pubmed/30546996
http://dx.doi.org/10.1007/s40629-018-0074-y
_version_ 1783375996069609472
author Klimek, Ludger
Kündig, Thomas
Kramer, Matthias F.
Guethoff, Sonja
Jensen-Jarolim, Erika
Schmidt-Weber, Carsten B.
Palomares, Oskar
Mohsen, Mona O.
Jakob, Thilo
Bachmann, Martin
author_facet Klimek, Ludger
Kündig, Thomas
Kramer, Matthias F.
Guethoff, Sonja
Jensen-Jarolim, Erika
Schmidt-Weber, Carsten B.
Palomares, Oskar
Mohsen, Mona O.
Jakob, Thilo
Bachmann, Martin
author_sort Klimek, Ludger
collection PubMed
description BACKGROUND: Apart from active allergen avoidance, immunotherapy is regarded as the most effective form of treatment available for type I allergies. Such treatments involve the administration of allergen preparations in various forms and by various routes. Virus-like particles (VLPs) offer a very effective platform for immunization with the allergen and are characterized by high immunogenicity, low allergenicity and high clinical efficacy. Formulations that include Toll-like receptor ligands, T cell stimulatory epitopes and/or depot-forming adjuvants appear to enhance activation of the relevant immune cells. Short nucleotide sequences including CpG motifs have also been intensively explored as potent stimulators of dendritic cells and B cells. METHODS: The present paper is based on a systematic literature search in PubMed and MEDLINE, and focuses on the pertinent immunological processes and on clinical data relating to use of VLPs and CpG motifs for the treatment of allergic rhinitis (AR). RESULTS: Many published studies have reported positive clinical results following administration of VLPs, either alone or in combination with CpG motifs and, in some cases, even in the absence of the allergen-specific allergen. CONCLUSIONS: These results indicate that VLPs modulate immune responses in ways which underline their exceptional promise as a platform for the immunotherapy of allergic disorders. However, clinical evaluations remain limited, and further large-scale and longer-term studies will be necessary to substantiate the efficacy and safety of these novel therapies.
format Online
Article
Text
id pubmed-6267129
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Springer Medizin
record_format MEDLINE/PubMed
spelling pubmed-62671292018-12-11 Virus-like particles (VLP) in prophylaxis and immunotherapy of allergic diseases Klimek, Ludger Kündig, Thomas Kramer, Matthias F. Guethoff, Sonja Jensen-Jarolim, Erika Schmidt-Weber, Carsten B. Palomares, Oskar Mohsen, Mona O. Jakob, Thilo Bachmann, Martin Allergo J Int Review BACKGROUND: Apart from active allergen avoidance, immunotherapy is regarded as the most effective form of treatment available for type I allergies. Such treatments involve the administration of allergen preparations in various forms and by various routes. Virus-like particles (VLPs) offer a very effective platform for immunization with the allergen and are characterized by high immunogenicity, low allergenicity and high clinical efficacy. Formulations that include Toll-like receptor ligands, T cell stimulatory epitopes and/or depot-forming adjuvants appear to enhance activation of the relevant immune cells. Short nucleotide sequences including CpG motifs have also been intensively explored as potent stimulators of dendritic cells and B cells. METHODS: The present paper is based on a systematic literature search in PubMed and MEDLINE, and focuses on the pertinent immunological processes and on clinical data relating to use of VLPs and CpG motifs for the treatment of allergic rhinitis (AR). RESULTS: Many published studies have reported positive clinical results following administration of VLPs, either alone or in combination with CpG motifs and, in some cases, even in the absence of the allergen-specific allergen. CONCLUSIONS: These results indicate that VLPs modulate immune responses in ways which underline their exceptional promise as a platform for the immunotherapy of allergic disorders. However, clinical evaluations remain limited, and further large-scale and longer-term studies will be necessary to substantiate the efficacy and safety of these novel therapies. Springer Medizin 2018-07-09 2018 /pmc/articles/PMC6267129/ /pubmed/30546996 http://dx.doi.org/10.1007/s40629-018-0074-y Text en © The Author(s) 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Review
Klimek, Ludger
Kündig, Thomas
Kramer, Matthias F.
Guethoff, Sonja
Jensen-Jarolim, Erika
Schmidt-Weber, Carsten B.
Palomares, Oskar
Mohsen, Mona O.
Jakob, Thilo
Bachmann, Martin
Virus-like particles (VLP) in prophylaxis and immunotherapy of allergic diseases
title Virus-like particles (VLP) in prophylaxis and immunotherapy of allergic diseases
title_full Virus-like particles (VLP) in prophylaxis and immunotherapy of allergic diseases
title_fullStr Virus-like particles (VLP) in prophylaxis and immunotherapy of allergic diseases
title_full_unstemmed Virus-like particles (VLP) in prophylaxis and immunotherapy of allergic diseases
title_short Virus-like particles (VLP) in prophylaxis and immunotherapy of allergic diseases
title_sort virus-like particles (vlp) in prophylaxis and immunotherapy of allergic diseases
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267129/
https://www.ncbi.nlm.nih.gov/pubmed/30546996
http://dx.doi.org/10.1007/s40629-018-0074-y
work_keys_str_mv AT klimekludger viruslikeparticlesvlpinprophylaxisandimmunotherapyofallergicdiseases
AT kundigthomas viruslikeparticlesvlpinprophylaxisandimmunotherapyofallergicdiseases
AT kramermatthiasf viruslikeparticlesvlpinprophylaxisandimmunotherapyofallergicdiseases
AT guethoffsonja viruslikeparticlesvlpinprophylaxisandimmunotherapyofallergicdiseases
AT jensenjarolimerika viruslikeparticlesvlpinprophylaxisandimmunotherapyofallergicdiseases
AT schmidtwebercarstenb viruslikeparticlesvlpinprophylaxisandimmunotherapyofallergicdiseases
AT palomaresoskar viruslikeparticlesvlpinprophylaxisandimmunotherapyofallergicdiseases
AT mohsenmonao viruslikeparticlesvlpinprophylaxisandimmunotherapyofallergicdiseases
AT jakobthilo viruslikeparticlesvlpinprophylaxisandimmunotherapyofallergicdiseases
AT bachmannmartin viruslikeparticlesvlpinprophylaxisandimmunotherapyofallergicdiseases